Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Plus
25
Ṁ11052030
77%
chance
1D
1W
1M
ALL
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy. Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein). The gene therapy must be for humans.
Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
Get
1,000and
1.00
1,0001.00Related questions
Related questions
Will there be an in-vivo gene therapy that edits multiple genes at once approved anywhere in the world before 2030?
52% chance
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
Will gene editing have cured at least one major disease by 2025?
95% chance
By 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
17% chance
The FDA will approve an AI developed cure before the end of the decade (<2030) for a previously incurable major illness.
54% chance
Will we have gene therapy for a major strain of Crohn's disease by 2030?
26% chance
Will a vaccine for HIV be approved by the FDA by 2030?
67% chance
Will a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
59% chance
Will there be an FDA-approved age reversal treatment based on partial cell reprogramming by 2030?
32% chance
Will I receive any kind of gene therapy created using CRISPR before I die?
59% chance